How UCB beat 2 other bidders to land $1.9B buyout of Zogenix and its epilepsy drug
Days before it would nail down the FDA’s approval for its epilepsy drug Fintepla, Zogenix received one of the first inquiries from a pharma company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
